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Abstract
Cancer stem cells (CSCs) appear to resist chemo-radiotherapy and initiate tumor recurrence in
patients. Isolation and further characterization of this subpopulation is important for targeting
CSCs. Flow cytometry using Aldefluor, a fluorescent substrate of aldehyde dehydrogenase, has
been used to isolate CSCs from various cancer cell lines. However, new techniques are needed to
locate and identify CSCs in culture for live-cell analyses such as fluorescence microscopy without
introducing artifacts during cell sorting and to observe CSC and non-CSC interactions. Previously,
we characterized a distinct CSC subpopulation within human esophageal cancer cell lines (ESCC).
In this study we introduce the attached-cell Aldefluor method (ACAM) to detect CSCs in ESCC
cell lines (KY-5, KY-10, TE-1, TE-8, YES-1, YES-2). To validate this technique, we isolated CSCs
from the YES-2 parental line using standard Aldefluor flow cytometry to create a cell line enriched
in CSCs (YES-2CSC). This line showed significantly greater ACAM staining and higher CD44 levels
than YES-2. ACAM also showed significantly higher ALDH activity in YES-2CSC than in YES-2S, a
cell line that has a diminished CSC subpopulation after having survived treatment with curcumin.
ACAM stained cells within tumorspheres made from the CSC-enriched line but not differentiating
cells from the tumorspheres. This study also demonstrates a new method for generating and
growing tumorspheres without the growth factor supplements normally used in medium to form
tumorspheres. ACAM should be evaluated using other cancer cell lines to further substantiate its
effectiveness and to characterize CSCs in culture through various imaging techniques.
Key words: Esophageal Cancer, Cancer Stem Cells, Aldefluor, Adherent Cells, CD44, Tumorsphere, Curcumin.

Introduction
Recent studies show that many solid tumors
contain a subpopulation of cells known as cancer stem
cells (CSCs) 1, 2. CSCs display stem cell characteristics
including self-renewal and differentiation into a heterogeneous population of cancer cells consisting of
progenitor cells and more differentiated cancer cells
3-5. It is likely that CSCs are responsible for initiation,
progression, recurrence, metastasis, and chemo-

radiotherapy resistance 6, 7. Additional methods to
identify and isolate CSCs are needed for their functional characterization and to develop effective therapeutics targeting this cell subpopulation 8. CSCs
have been identified and isolated from different cancer cell lines using several techniques. Tumor formation by CSCs in vivo is the most definitive method
for identifying these cells, but several in vitro methods
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are also effective. For example, fluorescence-activated
cell sorting (FACS) or magnetic cell separation are
used to isolate CSCs based on expression of specific
cell markers, such as the expression of CD24, CD44,
and CD133 9-11, although the presence of these surface
proteins varies considerably among CSCs of different
cancers. Another method is to use the fluorescent
Hoechst 33342 dye, which is used to isolate a
Hoechst-negative CSC “side population” 12. With this
method, however, the possible toxicity of the dye may
cause side effects during cell sorting 13, 14.
CSCs often have significantly elevated aldehyde
dehydrogenase (ALDH) activity 15. A substrate for
ALDH1, Aldefluor, was initially developed to isolate
hematopoietic stem cells using FACS 16. This Aldefluor method has been applied for separation of CSCs
from tumor tissue and cancer cell lines 17, 18. Aldefluor
has been used successfully to detect elevated ALDH1
activity in stem and progenitor cells of lung 18, prostate 19, breast 20, colon 21 and bladder 22 cancers.
Aldefluor contains the ALDH1 substrate
BODIPY-aminoacetaldehyde (BAAA) that is converted by ALDH1 into the fluorescent product
BODIPY-aminoacetate (BAA) 16, as described in the
product literature (Stem Cell Technologies). Live cells
retain BAA because of its charge and also because the
multidrug-resistance transporters are intentionally
inhibited by the Aldefluor reagents. Aldefluor treated
cells expressing high levels of ALDH1 activity have
high fluorescence and can be isolated with FACS into
two subpopulations—ALDH-hi and ALDH-low 17. Even
though this method has been used to identify CSCs
and has been validated for some cancers, it has not
been employed as widely as techniques that identify
CSC surface markers such as CD44 or CD133 23.
Although these flow cytometry methods are effective for quantifying CSCs and enriching the CSC
content of cell cultures, they have drawbacks and
limitations concerning the handling of the cells 24. For
example, they require cell trypsinization to produce
cells in suspension and in this state cells clump together and metabolism may be altered by poor access
to the medium. Cell handling can also induce stress,
disrupt gene expression, and lead to altered cell
physiology. To extend the usefulness of Aldefluor as a
stem cell marker, we assessed the use of Aldefluor
staining in cancer cells in adherent cell cultures, which
resulted in the attached-cell Aldefluor method
(ACAM). Being able to identify stem cells in live cell
monolayers with a technique such as ACAM has several advantages: (1) single-cell imaging of physiological processes within CSCs is much more practical in
monolayers than with cells in suspension or tumorsphere cultures, the typical method for growing
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CSCs 25; (2) the viability of CSCs in tumorspheres is
highly variable depending on cell access to the medium and effects from the microenviroment, whereas
monolayers have more uniform access to nutrients,
oxygen and mitogens such as epidermal growth factor
(EGF) and basic fibroblast growth factor (bFGF) 26, 27;
and (3) derivation of CSC cultures from tumors would
be aided by being able to identify live CSCs in monolayers 26. However, the standard Aldefluor technique
in which cells in suspension are stained remains a
valuable method for separating and collecting CSCs
from cultures.
Here we describe the use of ACAM with six
esophageal squamous cell carcinoma (ESCC) cell lines
that were used previously to evaluate curcumin effects on CSCs 28, Curcumin, an ingredient of the spice
turmeric, inhibits cancer cell growth 29, 30 including
ESCCs 31, 32 and reduces the number of CSCs in cancer
cell lines relative to the more differentiated cancer
cells 28, 33-35. One of our CSC-depleted ESCC lines,
YES-2S, that had survived curcumin treatment 28 was
used in the current study. In addition, to create a cell
line enriched in CSCs standard Aldefluor flow cytometry was applied to one of the ESCC lines, YES2,
and tested with ACAM.
CSCs have also been identified by their ability to
form tumorspheres in medium containing specific
growth factors 36, 37. Tumorspheres are enriched in
CSCs and the stem-like progenitor cells differentiating
from CSCs 38. We applied Aldefluor directly to ESCC
tumorspheres to test whether the cell types within the
tumorspheres could be distinguished by fluorescence
microscopy. Aldefluor has been used to detect CSCs
in cell suspensions derived from tumorspheres 39, 40,
but has not been used to stain intact tumorspheres in
culture. To further characterize tumorspheres in terms
of their CSC content, we examined tumorsphere formation, growth, sensitivity to curcumin, and ALDH1
activity. The present study discusses the potential
benefits of ACAM for investigating individual CSCs
in culture and is the first to demonstrate the usefulness of Aldefluor imaging in cancer cells growing as
monolayers or tumorspheres.

Materials and Methods
Cell lines and culture conditions
Human ESCC lines (KY-5, KY-10, TE-1, TE-8,
YES-1, and YES-2) were provided from various
sources 41-44, and they were previously characterized
immunologically and morphologically in our laboratory 28, 45 Cells were grown in a medium designated as
Complete medium that consisted of Dulbecco's modified Eagle medium (DMEM) containing penicillin (100
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units/ml), streptomycin (100 µg/ml), L-glutamine (2
mM) (Life Technologies, Grand Island, NY), and 10%
fetal bovine serum (FBS, Summit Biotechnology, Ft.
Collins, CO). Cells were grown in 100-mm tissue culture dishes (Falcon, Lincoln Park, NJ) at 37°C in 100%
humidity and 5% CO2. Cells were passaged when
they reached near confluency as described
previously28.

Aldefluor assay and separation of cells with
high-ALDH activity
ALDH activity was assayed in the YES-2 cell line
using the Aldefluor kit according to the manufacturer’s instructions (STEMCELL Technologies, Vancouver, BC, Canada). Briefly, 3 ml of a cell suspension (106
cells/ml in DMEM without serum) was centrifuged at
250 x g and resuspended in 3 ml of Aldefluor Buffer
on ice. To produce the fluorescent product, 45 μl of
activated Aldefluor substrate was mixed with 3 ml of
the cell suspension. Immediately after mixing, 1 ml
was used as the negative control by adding 30 μl of
diethylaminobenzaldehyde (DEAB), the ALDH1 inhibitor. The test sample and negative control were
incubated for 45 min at 37°C and agitated every 5 min.
These cells were centrifuged and resuspended in Aldefluor Buffer and kept on ice for one hour. The cells
were separated by flow cytometry using a FACSAria
III (BD Biosciences, San Jose, CA) based on fluorescence and cell scattering into two subpopulations—CSCs and non-CSCs. FACS was performed at
the Flow Cytometry Core Facility, University of Toledo, OH. After separation, cells were plated, grown
in culture, and stored at -80°C for future experiments.
Cell sorting data were analyzed with WinMDI 2.8
software.

Attached-cell Aldefluor method (ACAM)
To evaluate ACAM’s ability to determine
ALDH1 activity in ESCC lines, Aldefluor reagent was
used to stain attached ESCC cells. Each cell line was
grown on 25-mm glass coverslips in Complete medium. After 48 hours, the coverslips were washed
with Hank's Buffered Salt Solution (HBSS). One ml of
Aldefluor Buffer was added to 15 μl of activated Aldefluor, and 200 μl of this solution was added to each
coverslip which were then incubated for 45 min at
37°C in an incubator supplied with humidified air
containing 5% CO2. Next, the coverslips were washed
three times with HBSS and inverted on a chamber
containing 100 μl HBSS mounted on a glass microscope slide. Control coverslips did not receive the
activated Aldefluor, but were otherwise treated identically. The cells were examined with a fluorescence
microscope (Zeiss Axiophot, Carl Zeiss Microscopy
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LLC, Thornwood, NY) and imaged with a
cooled-CCD camera system (MicroMax Princeton
Instruments, Trenton, NJ). Images were analyzed with
Metamorph (Universal Imaging Corporation, Downingtown, PA), ImageJ (NIH), and OriginLab software
(OriginLab Corporation, Northampton, MA).

CD44 immunocytochemistry
The expression of CD44 in both the YES-2CSC
and YES-2 lines was examined as described previously 28. Briefly, each cell line was cultured on glass
coverslips, incubated for 48 hrs, and then washed
with PBS. Next, the cells were fixed with methanol for
5 min, washed with PBS three times, exposed to 0.3%
hydrogen peroxide for 3 min, and rinsed three times
with PBS. The cells were then incubated with normal
goat serum (NGS, Rockland, Gilbertsville, PA) at
1:100 dilution for 30 min at room temperature followed by mouse monoclonal anti-human CD44 antibody (BD Biosciences, Franklin Lakes, NJ) at 1:10 dilution for 2 hrs at room temperature. After three
rinses with PBS, the cells were incubated with goat
anti-mouse horseradish peroxidase-conjugated antibody (Sigma-Aldrich, St Louis, MO) at 1:40 dilution
for 30 min and then exposed to ImmunPACT diaminobenzidine for 10 min (Vector Laboratories,
Burlingame, CA). The cover slips were dehydrated in
an ethanol series, cleared with Citrosolve (Fisher,
Pittsburgh, PA), and mounted on glass slides with
Permount (Fisher, Pittsburgh, PA). Control cells were
treated identically but did not receive primary antibody.

Image analysis
The images of cell cultures immunostained for
CD44 were analyzed with ImageJ (NIH) and
OriginLab (OriginLab) software. Cell staining intensity was determined by imaging with a 12-bit digital
camera (MicroMax, Princeton Instruments) and a
Zeiss Axiophot microscope. The images were
thresholded identically using a pixel intensity
(brightness) value of 500 analog-to-digital units
(ADUs). For counting cells, ImageJ was used to identify cells within a normal size range (500-4000 pixels
in area) that did not touch the edge of the image.

Tumorsphere formation
To examine the tumorsphere formation, CSCs
isolated from the YES-2 line using FACS were grown
in tissue culture plates with Complete medium as a
monolayer until they reached near confluency. The
cells were trypsinized, collected, and washed three
times to remove the FBS. The cells were then cultured
in two different ways: (1) with Complete medium in a
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60-mm untreated petri dish or (2) with CSC medium
consisting of DMEM-F12 supplemented with 20
ng/ml EGF, 20 ng/ml bFGF and B27 supplement
(Invitrogen, Carlsbad, CA, USA) in a 60-mm ultra-low
attachment plate (Corning Life Sciences, Tewksbury,
MA). Cells were plated at a density of 104 cells/ plate
and incubated in a humidified atmosphere with 5%
CO2 at 37°C. One week later, plates were examined for
tumorsphere formation using an inverted microscope.
The tumorspheres were collected by gentle centrifugation, counted, and dissociated into single cells by
treatment with trypsin-EDTA and mechanical disruption using a glass Pasteur pipette. The resulting
single cells were resuspended in CSC medium or
Complete medium, washed with PBS, and plated to
allow tumorspheres to form again. Tumorspheres
were passaged every 5-7 days when they reached a
diameter about 100 μm.

Tumorsphere staining with Aldefluor
To assess the ability of ACAM to identify
ALDH1 activity in tumorspheres, Aldefluor was applied to tumorspheres cultured in CSC medium and
tumorspheres cultured in Complete medium in petri
dishes. Cover slips were rinsed with HBSS, and then 1
ml of Aldefluor Buffer was added to 15 μl of activated
Aldefluor and 100 μl of this solution was applied to
the coverslips for 45 min in a 37°C incubator. Next, the
Aldefluor reagent was removed, tumorspheres were
rinsed with HBSS, and propidium iodide (330 µg/ml)
was applied for 5 min. The cover slips were washed
three times with HBSS and the tumorspheres were
imaged with a digital camera (MicroMax, Princeton
Instruments) and a Zeiss Axiophot microscope.
Another group of tumorspheres were collected,
cultured on cover slips as attached tumorspheres in
Complete or CSC medium and incubated at 37°C in a
humidified incubator containing 5% CO2. In this case,
the tumorspheres were allowed to attach in a thin film
of medium for only 12 hrs before they were treated
with Aldefluor for 45 min at 37°C and then propidium
iodide as above just before imaging. Another group of
tumorspheres was not allowed to attach but was instead treated with Aldefluor, washed with HBSS by
centrifugation, treated with propidium iodide, and
then washed with HBSS. This low-speed 250 x g centrifugation caused the tumorspheres to fragment into
cell clusters.

Effect of curcumin on tumorspheres
To determine the effect of curcumin on the
growth of YES-2CSCs tumorspheres, spheres were
counted and cultured with 40 or 60 µM curcumin and
0.2% DMSO in Complete medium for 30 hrs. After
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incubation, tumorspheres were counted, the medium
was replaced with Complete medium without curcumin and incubated at 37°C for four days to allow
tumorspheres that survived the treatment to grow.
Tumorspheres were imaged after 30 hrs or 4 days of
treatment. Control tumorspheres were given medium
containing 0.2% DMSO.
To determine the effect of curcumin on tumorsphere formation, tumorspheres were collected,
dissociated into single cells using trypsin-EDTA and
mechanical disruption with a glass Pasteur pipette.
Resulting dissociated cells were resuspended in
Complete medium and washed by centrifugation. To
allow tumorspheres to form, cells were plated at a
density of 105 cells per 60-mm petri dish and either
treated with 40 µM curcumin after four days of plating or treated with 60 µM curcumin at the time of
plating and then incubated for 30 hrs, rinsed, and
imaged.

Tumorsphere proliferation
To compare the growth of cells derived from
dissociated tumorspheres that were made from
YES-2CSC with the ones made from the original
YES-2CSC cell line, tumorspheres were enzymatically
dissociated as described above, and 103 cells/well
were cultured in 12-well plates (Corning Life Sciences). The YES-2CSC line was plated at the same density. The cells were incubated for 10 days at 37°C in 5%
CO2. Cell proliferation was assayed with the crystal
violet staining method as described previously 28.

Statistical analysis
Statistical analyses were performed using
OriginPro 7.5 (OriginLab). Statistical comparisons
between two groups were made using Student’s t-test.
For comparing more than two groups, one-way analysis of variance (ANOVA) was used followed by the
Scheffe multiple comparisons test with a significance
of p<0.05. Variance was indicted as standard error of
the mean (SE).

Results
Isolation of cancer stem cells using Aldefluor
and FACS
The Aldefluor assay was used to assess the
presence of the subpopulation with high-ALDH enzyme activity within the YES-2 cell line. Cell suspensions were exposed to Aldefluor and then sorted by
FACS to count and collect the CSCs. Cell sorting results without Aldefluor treatment (control) is shown
in Figure 1A. A subpopulation with distinct fluorescence was present after Aldefluor treatment (Figure
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1B). When the ALDH inhibitor DEAB was applied at
the concentration suggested by the manufacturer (and
also used by others 46-48) fluorescence was reduced
(shifted to the left) and a gate was drawn to delineate
the upper limit of these cells (Figure 1C). This gate,
also shown in Figure 1B, was used to select for the
ALDH high-staining subpopulation in the following
cell sorting which used Aldefluor alone. The percentage of these highly fluorescent cells was 1.2% of
the YES-2 cell line and these cells were considered the
most stem-like cell subpopulation (YES-2CSC).
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Detection of Aldefluor fluorescence in attached ESCC cell lines
To identify CSCs in monolayer cultures, we applied Aldefluor to the attached ESCC cell lines. Fluorescence staining was detected in the cytoplasm of all
eight lines, including the YES-2CSC and YES-2S cell
lines as shown in Figure 2A. Measuring the staining
intensity of ALDH activity of individual cells indicated significant differences among the mean intensities of the cell lines (ANOVA, F=151.968, p<0.0001)
(Figure 2B). The order from high to low mean staining
intensity was as follows: KY-5, KY-10, YES-2CSC,
YES-1, TE-8, YES-2, TE-1, YES-2S (Figure 2C). KY-5
cells had significantly higher mean Aldeflour staining
than all the other cell lines (0<0.05, Scheffe test). The
range was 122 ±2.82 (YES-2S) to 320 ±6.01 (KY-5) analog-to-digital units (ADUs). There was no significant
difference between KY-10, YES-2CSC, YES-1, and
TE-8, whereas all of the other lines were distinctly
different from each other and from this intermediate
group. When YES-2 and the two YES-2-derived lines
were compared, they were found to be significantly
different (ANOVA, F=136.5, p<0.0001). YES-2CSC
had significantly higher ALDH activity than the
original YES-2 line (Figure 2D), which was in turn
higher than the curcumin-surviving line YES-2S
(p<0.05).

CD44 expression in YES-2 cell lines
As a second measure of stemness, immunostaining for the CSC marker CD44 was used.
YES-2CSC and the original line exhibited distinct high
and low-staining cells. The mean intensity between
the sorted (YES-2CSC) and original (YES-2) cell lines
was significantly different based on t-test (two-tailed,
t=-2.919, p=0.0036). YES-2CSC showed a higher percentage of positive cells (Figure 3).

Formation of tumorspheres

Fig 1. Flow cytometric isolation of cancer stem cells based on
ALDH activity. A: untreated control cells. B: Aldefluor-treated YES-2
cells in the absence of ALDH enzyme inhibitor DEAB. C: Aldefluor-treated
YES-2 cells in the presence of DEAB. The red line shows the gate used to
select for cells with high ALDH activity. SSC: side scatter.

Tumorspheres were formed from YES-2CSC in
two different ways: Cells were either grown in a
standard CSC medium in low-attachment plates
(Figure 4B) or in Complete medium in Petri plates
(Figure 4A). In both cases, tumorspheres formed
readily within one week. The tumorspheres formed in
Complete medium were more numerous, but the
CSC-medium tumorspheres were significantly more
circular according to ImageJ (0.923 ±0.0049 vs. 0.887
±0.0053, t-test, t=-4.949, p<0.0001). The average number of tumorspheres identified in Complete medium
was higher (74 ±3.21) than in the CSC-medium (28.3
±1.20), n=3 plates each. When tumorspheres made
from YES-2CSC were dissociated and plated in Complete medium, the resulting monolayer cultures prohttp://www.jcancer.org
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liferated about twice as fast as monolayer cultures
derived from the original YES-2CSC line during 10
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days of culture (0.0880 ±0.00221 vs. 0.0401 ±0.00477, t=
-9.11, p<0.0001).

Fig 2. Fluorescence intensity of ALDH1 reaction product in ESCC lines. A: Fluorescence in the ESCC lines, including YES-2CSC and YES-2S,
after Aldefluor was applied to attached cells growing in culture. Scale bar = 100 µm B: Histograms showing the distribution of relative ALDH activity in the
ESCC lines. C: Mean intensity of all ESCC lines. YES-2CSC is enriched in CSCs, and YES-2S is CSC-depleted. Oval indicates lines that are not significantly
different from each other. Asterisks indicate the significantly different YES-2 lines. D: YES-2CSC compared with YES-2 to indicate the increase in stem-like
cells in YES-2CSC. ADUs = Analog-to-digital units
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Fig 3. CD44 immunocytochemistry. Above: CD44-stained cells are visible in YES-2 and in the YES-2CSC line which has high-Aldefluor staining as
selected by FACS. Below: High CD44-staining cells are more abundant in the YES-2CSC line than in the YES-2 line. Scale bar = 100 µm

Fig 4. Tumorspheres derived from YES-2CSC. YES-2CSC cells form tumorspheres when cultured in Complete medium in a Petri dish (A) or in CSC
medium in a low-attachment plate (B). Scale bar = 100 µm

Live tumorspheres labeled with Aldefluor
To test whether ACAM would effectively identify the stem-like cells within tumorspheres, Aldefluor
was applied to tumorspheres made from YES-2CSC in
Complete medium and in CSC medium. The entire
sphere showed the fluorescent product of Aldefluor
in both media (Figure 5A and 5B) and in all tumorspheres examined. When tumorspheres were allowed to partially differentiate on a glass surface, the

cells proliferating from the tumorspheres were not
stained with Aldefluor (Figure 5C and 5D). These
results indicate that Aldefluor selects for the more
stem-like cells within the remaining tumorsphere that
have not differentiated. To better image individual
cells from the tumorspheres, centrifugation was used
to gently disrupt tumorspheres, the resulting cells
were imaged immediately and found to only be distinguishable by their distinct high or low-fluorescence
(Figure 5E and 5F).
http://www.jcancer.org
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Fig 5. ALDH activity of live tumorspheres. Tumorspheres were grown in Complete medium (A) or CSC medium (B), as in Figure 4, and then tested
for ALDH activity by applying Aldefluor for 45 min (A2, B2). Propidium iodide fluorescence indicated dying cells (A3, B3). Merged fluorescence is shown
in A4, B4 and as an overlay in A5, B5. Tumorspheres were allowed to attach to glass coverslips for 12 hrs in Complete medium (C1-5) and CSC medium
(D1-5). Differentiated cells present at the edges of both types of tumorspheres were not stained after applying Aldefluor (arrows). Sphere fragments
contained both high and low-Aldefluor staining in Complete medium (E1-5) and CSC medium (F1-5). Scale bar = 100 µm
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Fig 6. Effects of curcumin on primary and secondary tumorspheres. Left: Primary tumorspheres immediately after 40 µM (A) or 60 µM (B)
30-hr curcumin treatment and 4 days after 60 µM 30-hr treatment (C). Control YES-2CSC tumorspheres immediately after treatment with vehicle alone
for 30 hrs (D, E) and 4 days later (F). Note the irregular appearance of the treated tumorspheres. Right: Secondary tumorspheres, made from dissociated
primary tumorspheres, treated with 40 µM curcumin for 30 hrs 4 days after cell plating (G). Other tumorspheres treated with 60 µM curcumin for 30 hrs
at the time of plating and imaged immediately (H) or 4 days later (I). Control secondary tumorspheres imaged after 30 hrs of DMSO that was given after
4 days of growth (J) or when the cells were plated (K). Unlike the treated cells, control secondary sphere cells given 30 hrs of DMSO at the time of plating
and then imaged 4 days later formed tumorspheres (L). Scale bar = 100 µm.

Sphere inhibition by curcumin treatments
To determine the effect of curcumin on tumorspheres enriched with stem cells, YES-2CSC tumorspheres that developed in culture for 10 days
were treated with 40 or 60 µM curcumin for 30 hrs.
Sphere cultures were examined immediately after
treatments and 4 days later. These primary tumorspheres are shown in Figure 6, left panel. Tumorspheres had more irregular margins when imaged
after 30 hrs of 40 µM (Figure 6A) or 60 µM (Figure 6B)
curcumin or, instead, 4 days after 30 hrs of 60 µM
curcumin (Figure 6C). Control tumorspheres were
imaged immediately (Figure 6D and 6E) and 4 days
after treatment with 30 hrs of 0.2% DMSO (vehicle) in
medium (Figure 6F). Also, 40 µM curcumin for 30 hrs
significantly reduced the number of tumorspheres
from (393 ±14.26) before to (162 ±20.69) after treatment
(p= 0.001, t=9.192, n=3 plates).
We also examined secondary tumorspheres that
were formed from trypsin-dissociated tumorspheres
(Figure 6, right panel). After 4 days of culture, these
tumorspheres were treated with 40 µM curcumin for
30 hrs causing them to become so irregularly-shaped
(Figure 6G) relative to the control (Figure 6J) that they
could not be counted reliably as spheres. Cells from
dissociated tumorspheres were treated with 60 µM
curcumin for 30 hrs at the time the cells were plated.
This treatment prevented tumorspheres from forming

when imaged immediately after (Figure 6H) and 4
days later (Figure 6I) relative to controls (Figure 6K
and 6L), respectively.

Discussion
Among the few current methods available to
distinguish the stem-like cells from the remaining
cancer cells is ALDH immunocytochemistry 28 or the
standard Aldefluor enzyme assay. During the Aldefluor assay, a fluorescent product is deposited in live
cells in response to the high ALDH content of CSCs.
We expected the fluorescence intensity to vary because ALDH activity varies between CSCs due to
differences in their differentiation state. The distribution of high Aldefluor-staining cells we detected by
FACS in the YES-2 line is best explained by a variation
in stem-like properties, as found in other cancer
lines 49.
When the ALDH1 inhibitor DEAB was used in
the assay, cell fluorescence decreased substantially
but remained above the unstained cell population that
consists of non-CSCs. It appears that stemness varies
continuously in this cell line, and possibly others, as
indicated by the range of Aldefluor staining in the
ACAM histograms (Figure 2). By selecting for only
the cells at the upper range of Aldefluor fluorescence,
where no cells remained in the DEAB-treated assay,
we generated an additional cell line (YES-2CSC) that
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contains, conservatively, the most stem-like component of the YES-2 line. We suspect that many of the
cells that stain less effectively can be considered the
progenitor cells that are generated from CSCs and
then proliferate and further differentiate to form the
bulk of tumors 50, 51. Similar low-staining populations
were present in other studies using DEAB with Aldefluor 46-48, 52, further supporting the idea that these are
progenitor cells with lower ALDH activity relative to
CSCs. To confirm this possibility of using Aldefluor to
identify progenitor cells, additional studies should
examine co-localization of Aldefluor with a second
stem cell marker, such as CD44, to test for a decline in
both markers within these putative progenitor cells in
relation to the expression levels in CSCs.
This heterogeneity of cells stained within the
Aldefluor assay suggested initially that cells of a distinctly different morphology may be present in cancer
cell lines and that the fluorescence intensity may correlate with cell shape. To address this possibility, the
Aldefluor substrate was applied to six ESCC cell lines
using ACAM. We observed both high and
low-staining cells, but no cells of a distinctly different
shape or size were distinguishable by ACAM in this
cancer cell type.
When the cell lines were arranged according to
mean fluorescent intensity, the order was similar to
that of a previous study in which ALDH1A1 immunocytochemistry was used to characterize these
cell lines 28, verifying the accuracy of ACAM at distinguishing between cell lines according to their CSC
content. Specifically, the highest and lowest staining
cell lines were the same in both assays, although not
all intermediate-staining lines followed the same order. It should be noted that ACAM is particularly
useful with epithelial cells such as the ESCC lines because they readily form a monolayer in culture.
Because this is the first reported use of Aldefluor
in an attached-cell assay of stemness, we examined
how it might be an alternative and complementary
method to standard Aldefluor flow cytometry. First,
we considered the limitations of the standard method.
In addition to a lack of validation for some types of
cancer stem cells, there are several other drawbacks
and limitations to the Aldefluor procedure concerning
the handling of the cells during the assay. During the
standard Aldefluor procedure, suspended cells are
subjected to increased cell stress in response to physiological or environmental effects that monolayers do
not experience. The suspended cells are incubated
with the reagent for 30 to 60 min and are then kept on
ice until cell sorting, a step that will affect overall enzyme activity. The cell aggregation produced during
centrifugation and processing could cause poor access
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to oxygen or glucose and buildup of lactic acid and
CO2 near the cells. Excessive CO2 levels produce respiratory acidosis that alters cell metabolism 27. In fact,
these stressors could act differentially on CSCs and
non-CSCs resulting in an altered ratio of these two
subpopulations. Another known effect of the standard
Aldefluor assay is the intentional inhibition of the
multidrug-resistance transporter system 16. When the
reagent is added, the efflux is specifically inhibited in
the suspended cells by the Aldefluor Buffer and this
suppression of the transporter can alter cell physiology during sorting, whereas ACAM does not require
the inhibitor during imaging thus avoiding its potential side effects. Taken together, these reasons provide
adequate incentive to further develop ACAM as an
alternative and complementary method to the standard flow cytometry method with Aldefluor.
To further verify the accuracy of using Aldefluor
on attached cells, the Aldefluor substrate was also
applied to the original line, the curcumin-surviving
line, and the CSC-sorted cell line (YES-2, YES-2S, and
YES-2CSC, respectively). The results showed that
YES-2CSC had higher Aldefluor staining than the
other cell lines and the curcumin-surviving cells had
the lowest. These results indicate that ACAM is advantageous for detecting CSCs in adherent cells.
CD44 is a commonly expressed CSC marker that
is observed in many cancer cell lines, including ESCC,
and is also identifiable by immunostaining or FACS 28,
53, 54. The positive CD44 cells detected in the YES-2 and
YES-2CSC lines confirm our results from ACAM and
Aldefluor-based FACS. The YES-2CSCs showed more
CD44 staining than the original YES-2 line and had
higher mean fluorescence using ACAM, indicating
again that ACAM is able to quantify the stem-like
state of a cancer cell line that has been enriched in
CSCs using FACS.
We also tested ACAM as a method to identify
CSCs in tumorspheres using Aldefluor. A few studies
have used Aldefluor to detect CSCs in cell suspension
made from tumorspheres 39, 40, but no prior studies
have used Aldefluor to stain the intact sphere. The
results of the current report show the feasibility of this
approach. When tumorspheres were grown by two
different methods and then allowed to partially differentiate, Aldefluor treatment stained a major portion of all of the tumorspheres, but differentiating
cells at the margin of the tumorspheres did not stain
(Figure 5). To determine whether the differential
staining we observed in monolayers of ESCC cells
would be present in cells growing as tumorspheres,
we applied Aldefluor to fragments produced by gentle centrifugation of tumorspheres, and again both
high and low-staining cells were present. These initial
http://www.jcancer.org
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results suggest that Aldefluor staining may also distinguish between CSCs, progenitor cells, and more
differentiated cells within tumorspheres based on
staining intensity (Figure 5).
The stemness and number of CSCs that remains
in a cell line previously enriched in CSCs could
change spontaneously during repeated passaging.
The number of YES2-CSC passages used in the tumorsphere experiments ranged from 2 to 9 (average
5.8), whereas the ACAM and CD44 experiments used
YES2-CSC cells after only 2 to 4 passages. Nevertheless, the ability to form primary and secondary
spheres (Figure 6), which is an indicator of stemness,
was not lost during passaging. Therefore, any ability
of one cell subpopulation within YES2-CSC to grow
faster and alter the CSC content of the cell line was not
obvious from these results.
Tumorspheres enriched in CSCs can be formed
when cancer cells are cultured in serum-free medium
supplemented with growth factors, specifically bFGF
and EGF, during culture in low-attachment plates 55.
Although use of this culture technique with CSC medium is effective, it is costly and therefore less accessible than other cell culture methods. Our study discovered that use of standard CSC media with
low-attachment plates is not required for sphere formation from the YES-2CSC cell line. As a more affordable alternative, we showed that ultralow-attachment plates could be replaced with a
standard non-cell culture Petri dish when the CSC
medium is replaced with Complete medium which
contains FBS. In contrast, when CSC medium was
used with the Petri dish the cells attached and differentiated and no tumorspheres formed (data not
shown). The new method yielded more tumorspheres
than the standard method, and when dissociated the
cells proliferated faster than the original YES-2CSC
line, suggesting that these tumorspheres had high
CSCs content.
Although tumorspheres formed by the two
methods appear to be very similar, the new method
could have produced tumorspheres with fewer CSCs.
To further test tumorspheres made by the new
method, we prepared tumorspheres from the
YES-2CSC line in Complete medium and treated them
with curcumin which is reported to more effectively
eliminate CSCs than non-stem cells in different cancer
cell types 56, 57. For example, our previous research
showed a reduction in ALDH1A1-positive cells in six
curcumin-surviving ESCC lines by immunocytochemistry 28. Curcumin causes cell death in a variety
of ways by targeting, membrane receptors, cytokines,
kinases, and transcription factors 34. Moreover, curcumin effects seem to persist despite the typical
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chemo-resistant capabilities of CSCs and even select
against CSCs, significantly reducing the number of
cells showing CSC-markers in colon, glioma, and
ESCC lines 28, 56, 57.
Our result showed that curcumin at 60 µM prevented secondary sphere formation from tumorspheres formed by the new method and 40 µM
produced irregularly shaped spheres. These poorly
shaped spheres suggest that cell interactions or extracellular matrix through which CSCs communicate
may be disrupted. A recent study by Subramaniam, et
al., 58 showed that curcumin treatment significantly
reduces both primary and secondary sphere formation in a dose dependent manner in two ESCCs
(TE-7 and TE-10). Similarly, we found that initial
formation of secondary tumorspheres made by the
new method was as effectively eliminated by 60 µM
curcumin as tumorspheres made by the standard
method that were given 50 µM curcumin, as reported
previously 58. Based on these inhibitory effects of
curcumin the new method likely produces tumorspheres enriched in CSCs. Furthermore, tumorspheres formed by both the new and standard
methods were indistinguishable when stained by Aldefluor. Using another approach, Aldefluor has been
shown to stain live neural stem and progenitor cells in
the subventricular zone of mouse brain following
intraventricular injection of the reagent 59, supporting
novel use of Aldefluor, including ACAM, for identifying CSCs by microscopy.

Conclusion
Our study demonstrated the feasibility of identifying CSCs by using Aldefluor to stain live attached
cells growing as monolayers. The benefit of detecting
CSCs in attached cells with Aldefluor, rather than in
cell suspensions, is that the cells can be imaged directly to evaluate morphology and intracellular dynamics of live cells. We also introduced and evaluated
an alternative method for forming tumorspheres using ordinary Petri dishes and Complete medium. The
finding that both YES-2CSC monolayers and tumorspheres are sensitive to curcumin provides further evidence that one of the mechanisms by which
curcumin inhibits cancer cell growth is by targeting
CSCs. It is likely that the two new methods introduced in this paper for detecting CSCs and producing
tumorspheres would be valuable when used in CSC
studies of other cancers.
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